Country Specific information


 Canada


United Kingdom


 USA

back


PUBLICATIONS AND PRESENTATIONS

Peer Reviewed papers

  1. Study Conduct, Monitoring and Data Management in a Tri-National AIDS Trial: The OPTIMA Model. Kyriakides TC., Babiker A., Singer J., Piaseczny M., Russo J. on behalf of the OPTIMA Team. Clinical Trials 2004; 1: 277-281 Click here to see full paper
  2. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA trial. Kyriakides TC., Babiker A., Singer J., Cameron W., Schechter M., Brown S., Holodniy M., Youle M., Gazzard B. and the OPTIMA Team. Controlled Clinical Trials, 24;4: 481-500. Click here to see full paper

Oral Presentations

  1. The effect of hepatitis C virus on HIV progression in a late salvage population: results from the OPTIMA study. Ewings F, Angus BJ, Brown S, Cameron DW, Holodniy M, Kyriakides TC, Singer J, Babiker A. HIV Medicine journal, which has all the oral presentations - HIV Med 7 (supplement 1), abstract 015, 2006 Click here to see abstract
  2. Validation of Initial Plasma Viremia Response to Salvage Therapy for AIDS with Multi-Drug Resistant HIV as a Surrogate Marker of Clinical Efficacy in the OPTIMA Trial. J. Singer, K. Wu, W. Cameron, Anis A., M. Holodniy, S.T. Brown, , T.C. Kyriakides, A. Babiker for the OPTIMA Study Team. 14th Annual Canadian Conference on HIV/AIDS Research, Vancouver, BC, May 12-15, 2005
  3. The impact of AIDS-Defining Events and Serious Adverse Events (SAE) in Patients with Advanced HIV disease in the OPTIMA trial: What affects patients Quality of Life most? AH Anis, H Sun, J Singer, DW Cameron, D Owens, S Brown, MJ Sculpher, MT Schechter for the OPTIMA trial group. Canadian HIV Trials Network, US Department of Veterans Affairs and the Medical Research Council Clinical Trials Unit (UK).14th Annual Canadian Conference on HIV/AIDS Research, Vancouver, BC, May 12-15, 2005
  4. Utility-Based Assessments of Quality of Life in a Randomized Trial of Antiretroviral Therapy in Advanced HIV Disease Joyce V., Araki SS., Sundaram V., Hill AK., Baker F., Munakata J, Kyriakides TC., Sanders GD., Griffin SC., Holodniy M., Brown S., Sculpher M., Anis AH., Yu W., Owens DK., and the OPTIMA Investigators. Society for Medical Decision Making 2004 Annual Meeting, Atlanta, GA, October 17-20, 2004
  5. Development of a Shared electronic database and the MedDRA dictionary to code adverse events for a tri-national HIV/AIDS study Swanson KM., Kyriakides TC. Del Curto B., Russo J., Raisch D. Oral Presentation, Society for Clinical Trials Annual Meeting, London, U.K, July 20-24, 2003 Click here to see full presentation
  6. Design of the OPTIMA Trial. Brown S., Youle M. for the OPTIMA Team. 3rd International Workshop on Structured Treatment Interruptions, Montreal, Canada, March 22-24, 2002. Click here to see abstract
  7. The OPTIMA Study.Youle M., Brown S. for the OPTIMA Team. 2nd International Workshop on Structured Treatment Interruptions, Schaumburg, Ill, October 13-15, 2000. Click here to see abstract

Poster Presentations

  1. Predictors of Clinical Response to Salvage Therapy in a Late Salvage Population with Multidrug-resistant HIV in the OPTIMA Trial. Singer J, Ayers D, Cameron DW, Holodniy M, Brown S, Kyriakides TC, Babiker A, Anis A, Youle M, Schechter M and Darbyshire J for the OPTIMA Study Team 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8, 2006. Click here to see full poster
  2. Predictors of Clinical Response to Salvage Therapy in a Late Salvage Population with Multidrug-resistant HIV in the OPTIMA Trial. Singer J., Ayers D., Cameron DW., Holodniy M., Brown ST, Kyriakides TC., Babiker A., Anis A., Youle M., Schechter MT and Darbyshire J. for the OPTIMA Study Team 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8, 2006. Poster #526.
  3. The Impact of AIDS-defining Events and Serious Adverse Events (SAE) in Patients With Advanced HIV Disease in the OPTIMA Trial. AH Anis, H Sun, J Singer, DW Cameron, DK Owens, ST Brown, M Holodniy, MJ Sculpher, MT Schechter for the OPTIMA Trial Group.Treatment and Management of HIV Infection in the United States. Atlanta, GA, September 15-18, 2005.
  4. The Longitudintal Pattern of Health Utility and its Determinants Among Patients Undergoing Salvage Treatment in the OPTIMA Trial. AH Anis, H Sun, J Singer, D Guh, DW Cameron, DK Owens, S Brown, M Holodniy, MJ Sculpher, MT Schechter for the OPTIMA Trial Group. Treatment and Management of HIV Infection in the United States. Atlanta, GA, September 15-18, 2005.
  5. Response of Initial Plasma Viremia to Salvage Therapy for Multi-Drug Resistant HIV as a surrogate marker of Clinical Efficacy in the OPTIMA Trial.S Brown, J Singer, K Wu, M Holodniy, BD Cameron TC Kyriakides, A Babiker, A Anis, M Youle, MT Schechter for the OPTIMA Study Team. Treatment and Management of HIV Infection in the United States. Atlanta, GA, September 15-18, 2005.
  6. Early HIV-RNA Response predicts clinical Outcomes in a late salvage population.J. Singer, K. Wu, W. Cameron, Anis A, M. Holodniy, S.T. Brown, T.C. Kyriakides, A. Babiker for the OPTIMA Study Team. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, July 24-27, 2005. Poster WePe12.9C02
  7. AIDS-Defining Events and Serious Adverse Events (SAE) in Patients with Advanced HIV disease in the OPTIMA trial: What affects patients Quality of Life most? AH Anis, H Sun, J Singer, DW Cameron, DK Owens, S Brown, MJ Sculpher, MT Schechter for the OPTIMA trial group. Canadian HIV Trials Network, US Department of Veterans Affairs, UK Medical Research Council, York University, University of Ottawa, Centre for Health Evaluation and Outcome Sciences. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, July 24-27, 2005. Poster WePe12.9C04
  8. The Longitudinal Pattern of Health Utility and its Determinants among Patients on Salvage Regimens with or without a Prior Treatment Interruption. AH Anis, H Sun, J Singer, D Guh, X Li, DW Cameron, DK Owens, S Brown, M Holodniy, T Kyriakides, A Babiker, MJ Sculpher, M Youle, MT Schechter for the OPTIMA trial group. Canadian HIV Trials Network, US Department of Veterans Affairs, UK Medical Research Council, York University, University of Ottawa, Royal Free Hospital (London), Centre for Health Evaluation and Outcome Sciences. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, July 24-27, 2005. Poster WePe12.9C18
  9. Relative Impact of Esophageal Candidiasis (EC) Versus Other AIDS Events in the OPTIMA Trial. DW. Cameron, S Brown, M Youle, A Anis, H Sun and J Singer for the OPTIMA Trial group. Poster Presentation, 14th Annual Canadian Conference on HIV/AIDS Research, Vancouver, BC, May 12-15, 2005.
  10. The Impact of AIDS-Related Events and Non-AIDS Serious Adverse Events on Health-Related Quality of Life in a Multinational Trial of Antiretroviral Therapy. Aalfs SSA., Guh D., Singer J., Joyce V., Sundaram V., Munakata J., Hill AK., Sun H., Griffin SC., Sanders GD., Bayoumi A., Holodniy M., Brown S., Sculpher MJ., Yu W., Owens DK., Anis A., and the OPTIMA Team Society for Medical Decision Making 2004 Annual Meeting, Atlanta, GA, October 17-20, 2004. Medical Decision Making 25 (1): E52.
  11. Non-AIDS Serious Adverse Events are as Important as AIDS Events in Patients with Advanced Multi-Drug Resistant HIV disease S.T. Brown, J. Singer, A. Anis, T.C. Kyriakides, W. Cameron, M.Holodniy, B.J. Angus, A. Babiker, K. Swanson, H. Sun.XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004 Poster MoPeD3841 Click here to see full poster
  12. Baseline Characteristics, Antiretroviral Resistance Profile and Clinical Events in the OPTIMA Trial: A Preliminary Report M. Holodniy, B. Angus, S. Brown, A. Babiker, W.Cameron, B. Gazzard, T. Kyriakides, J. Singer, M.Youle, for the OPTIMA Team Study Team. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004 Poster TuPeB4578 Click here to see full poster
  13. Baseline Antiretroviral Resistance Profile and Correlation with Clinical Events in the OPTIMA Trial. M. Holodniy, J. Singer, R. Woods, P.R Harrigan, S.T.Brown, W.Cameron, T.C. Kyriakides, B.J. Angus, A. Babiker, for the OPTIMA Team Study Team. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004 Poster WePeB5727 Click here to see full poster
  14. The Impact of Non-AIDS Serious Adverse Events Equals or Exceeds that of AIDS Outcomes in Patients with Advanced Multi-Drug Resistant HIV Disease. S.T Brown, J. Singer, A. Anis, H. Sun, T.C. Kyriakides, B.J. Angus, K. Swanson, W. Cameron, A. Babiker, M. Holodniy, and The OPTIMA Study Team. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11, 2004 Click here to see abstract
  15. Data Management in a Tri-National AIDS Trial. Babiker A., Singer J., Kyriakides TC., Piaseczny M., Russo J., Goodall R.; for the OPTIMA Team. Society for Clinical Trials Annual Meeting, London, U.K, July 20-24, 2003 Click here to see full poster
  16. Design of a prospective economic evaluation for a tri-national clinical trial in HIV patients (OPTIMA) Munakata J., Woolcott J., Anis A., Sculpher M., Yu W., Sanders G., Bayoumi A., Gubinas V., Philips Z., Owens D. for the OPTIMA Team. Society for Clinical Trials Annual Meeting, London, U.K, July 20-24, 2003 Click here to see full poster
  17. Baseline Characteristics, antiretroviral treatment, randomization and clinical events in the OPTIMA Trial: A preliminary report. Holodniy M., Angus B., Brown S., Babiker A., Cameron W., Gazzard B., Kyriakides T., Singer J., Youle M., for the OPTIMA Study Team. International AIDS Society, 2nd Conference on HIV Pathogenesis and Treatment, Paris, July 13-16, 2003. Poster #584 Click here to see full poster
  18. An Open-Label Randomized Clinical Trial of Novel Therapeutic Strategies for Patients in Whom Antiretroviral Therapy has Failed: Design, Rationale and Methods of the OPTIMA Trial. Kyriakides TC., Babiker A., Singer J., Cameron W., Brown S., Holodniy M., Youle M., Gazzard B., Deyton L., Darbyshire J., Schechter M., and the OPTIMA Team.Society for Clinical Trials Annual Meeting, Arlington, VA, May 12-15, 2002 Click here to see full poster

Last updated: 18/07/06